{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:50:04Z","timestamp":1793814604870,"version":"4.6.1"},"reference-count":157,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1093\/annonc\/mdy551","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T15:10:47Z","timestamp":1546528247000},"page":"219-235","source":"Crossref","is-referenced-by-count":525,"title":["Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors"],"prefix":"10.1016","volume":"30","author":[{"given":"K.M.","family":"Heinhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdy551_bb0010","first-page":"802","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"71","author":"Larkin","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy551_bb0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1093\/annonc\/mdy551_bb0020","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1093\/annonc\/mdy551_bb0025","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1634\/theoncologist.2017-0087","article-title":"FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum\u2010containing chemotherapy","volume":"22","author":"Ning","year":"2017","journal-title":"Oncologist"},{"issue":"5","key":"10.1093\/annonc\/mdy551_bb0030","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"Oncologist"},{"issue":"47","key":"10.1093\/annonc\/mdy551_bb0035","doi-asserted-by":"crossref","first-page":"77404","DOI":"10.18632\/oncotarget.12677","article-title":"Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy","volume":"7","author":"Nakamura","year":"2016","journal-title":"Oncotarget"},{"key":"10.1093\/annonc\/mdy551_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"issue":"21","key":"10.1093\/annonc\/mdy551_bb0045","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy551_bb0050","article-title":"Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC) results from KEYNOTE-086","volume":"28","author":"Loi","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdy551_bb0055","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","article-title":"Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdy551_bb0060","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00262-014-1545-8","article-title":"Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma","volume":"63","author":"Simeone","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0065","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12967-017-1348-8","article-title":"Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab","volume":"15","author":"Morello","year":"2017","journal-title":"J Transl Med"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"issue":"6230","key":"10.1093\/annonc\/mdy551_bb0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"23","key":"10.1093\/annonc\/mdy551_bb0080","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"10031","key":"10.1093\/annonc\/mdy551_bb0085","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1093\/annonc\/mdy551_bb0090","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1093\/annonc\/mdy551_bb0095","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7528","key":"10.1093\/annonc\/mdy551_bb0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0105","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2017.35.15_suppl.4012","article-title":"KEYNOTE-059 cohort 2: safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer","volume":"35","author":"Bang","year":"2017","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1093\/annonc\/mdy551_bb0110","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort","volume":"34","author":"Chow","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy551_bb0115","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"1","author":"Kim","year":"2018","journal-title":"Nat Med"},{"issue":"17","key":"10.1093\/annonc\/mdy551_bb0120","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","article-title":"Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma","volume":"23","author":"Vilain","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7528","key":"10.1093\/annonc\/mdy551_bb0125","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1093\/annonc\/mdy551_bb0130","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0135","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1479-5876-9-204","article-title":"A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma","volume":"9","author":"Hamid","year":"2011","journal-title":"J Transl Med"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1479-5876-10-146","article-title":"Biomarkers on melanoma patient T cells associated with ipilimumab treatment","volume":"10","author":"Wang","year":"2012","journal-title":"J Transl Med"},{"key":"10.1093\/annonc\/mdy551_bb0145","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejca.2016.12.031","article-title":"The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab","volume":"75","author":"Tietze","year":"2017","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdy551_bb0150","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/exd.13263","article-title":"Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy","volume":"26","author":"Tietze","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1093\/annonc\/mdy551_bb0155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ebiom.2017.03.029","article-title":"Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment","volume":"18","author":"Cassidy","year":"2017","journal-title":"EBioMedicine"},{"issue":"24","key":"10.1093\/annonc\/mdy551_bb0160","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","article-title":"Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab","volume":"21","author":"Gebhardt","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1093\/annonc\/mdy551_bb0165","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/annonc\/mdw016","article-title":"Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab","volume":"27","author":"Ferrucci","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy551_bb0170","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2326-6066.CIR-14-0013","article-title":"Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes","volume":"2","author":"Kitano","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"10.1093\/annonc\/mdy551_bb0175","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-15-3104","article-title":"Clinical significance of circulating CD33+CD11b+HLA-DR- myeloid cells in patients with stage IV melanoma treated with ipilimumab","volume":"22","author":"Sade-Feldman","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdy551_bb0180","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/cas.13226","article-title":"Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma","volume":"108","author":"Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1093\/annonc\/mdy551_bb0185","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat Med"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0190","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/jco.2015.33.15_suppl.3001","article-title":"Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature","volume":"33","author":"Ribas","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdy551_bb0195","doi-asserted-by":"crossref","first-page":"P80","DOI":"10.1186\/2051-1426-3-S2-P80","article-title":"Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors","volume":"3","author":"Ayers","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0200","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2017.35.15_suppl.4502","article-title":"Biomarker findings and mature clinical results from KEYNOTE-052 first-line pembrolizumab in cisplatin-ineligible advanced urothelial cancer","volume":"35","author":"O\u2019Donnell","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdy551_bb0205","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Cancer Res"},{"issue":"10030","key":"10.1093\/annonc\/mdy551_bb0210","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdy551_bb0215","unstructured":"U.S. Food and Drug Administration. Opdivo (nivolumab) Prescribing information, 2015. Reference ID: 4198384."},{"key":"10.1093\/annonc\/mdy551_bb0220","unstructured":"U.S. Food and Drug Administration. Keytruda (pembrolizumab) 2018: 1\u201353; Reference ID: 4276421."},{"issue":"7463","key":"10.1093\/annonc\/mdy551_bb0225","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"9","key":"10.1093\/annonc\/mdy551_bb0230","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1470-2045(17)30512-0","article-title":"PD-1 inhibition in metastatic dMMR\/MSI-H colorectal cancer","volume":"18","author":"Sclafani","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy551_bb0235","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1093\/annonc\/mdy551_bb0240","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"issue":"8","key":"10.1093\/annonc\/mdy551_bb0245","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdy551_bb0250","doi-asserted-by":"crossref","first-page":"S717","DOI":"10.1016\/S0959-8049(16)31937-2","article-title":"15LBA high tumoral IFN\u03b3 mRNA, PD-L1 protein, and combined IFN\u03b3 mRNA\/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients","volume":"51","author":"Higgs","year":"2015","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdy551_bb0255","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0260","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3164\/jcbn.12-60","article-title":"Effects of anticancer agents on cell viability, proliferative activity and cytokine production of peripheral blood mononuclear cells","volume":"52","author":"Sakai","year":"2013","journal-title":"J Clin Biochem Nutr"},{"issue":"4","key":"10.1093\/annonc\/mdy551_bb0265","doi-asserted-by":"crossref","first-page":"e1008866","DOI":"10.1080\/2162402X.2015.1008866","article-title":"Trial Watch: immunogenic cell death inducers for anticancer chemotherapy","volume":"4","author":"Pol","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0270","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00262-010-0926-x","article-title":"Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells","volume":"60","author":"Haggerty","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1093\/annonc\/mdy551_bb0275","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/jnci\/djx257","article-title":"The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy","volume":"110","author":"McKenzie","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1093\/annonc\/mdy551_bb0280","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/1547691X.2012.693547","article-title":"Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential","volume":"9","author":"Frey","year":"2012","journal-title":"J Immunotoxicol"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0285","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1479-5876-9-77","article-title":"Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy","volume":"9","author":"Alagkiozidis","year":"2011","journal-title":"J Transl Med"},{"key":"10.1093\/annonc\/mdy551_bb0290","article-title":"Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells","author":"Wan","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1093\/annonc\/mdy551_bb0295","first-page":"1107","article-title":"Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study","volume":"9","author":"Ferrari","year":"2002","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1093\/annonc\/mdy551_bb0300","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"22","key":"10.1093\/annonc\/mdy551_bb0305","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.4161\/cc.8.22.10026","article-title":"Chemotherapy induces ATP release from tumor cells","volume":"8","author":"Martins","year":"2009","journal-title":"Cell Cycle"},{"issue":"14","key":"10.1093\/annonc\/mdy551_bb0310","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human tumor cells killed by anthracyclines induce a tumor-specific immune response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdy551_bb0315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cyto.2017.05.024","article-title":"Cytokines in immunogenic cell death: applications for cancer immunotherapy","volume":"97","author":"Showalter","year":"2017","journal-title":"Cytokine"},{"issue":"12","key":"10.1093\/annonc\/mdy551_bb0320","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"issue":"11","key":"10.1093\/annonc\/mdy551_bb0325","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0330","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1093\/annonc\/mdy551_bb0335","doi-asserted-by":"crossref","first-page":"e0156643","DOI":"10.1371\/journal.pone.0156643","article-title":"Epirubicin, identified using a novel luciferase reporter assay for Foxp3 inhibitors, inhibits regulatory T cell activity","volume":"11","author":"Kashima","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1093\/annonc\/mdy551_bb0340","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0277-5379(90)90142-G","article-title":"Changes in T lymphocyte subsets after single dose epirubicin","volume":"26","author":"Lissoni","year":"1990","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdy551_bb0345","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.cdd.4400595","article-title":"The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes","volume":"7","author":"Ferraro","year":"2000","journal-title":"Cell Death Differ"},{"issue":"2","key":"10.1093\/annonc\/mdy551_bb0350","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10637-010-9603-3","article-title":"A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model","volume":"30","author":"Quartino","year":"2012","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1093\/annonc\/mdy551_bb0355","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/1097-0142(20000915)89:6<1380::AID-CNCR23>3.0.CO;2-R","article-title":"Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis","volume":"89","author":"Kotsakis","year":"2000","journal-title":"Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdy551_bb0360","first-page":"1286","article-title":"Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug taxol","volume":"54","author":"Chuang","year":"1994","journal-title":"Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdy551_bb0365","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000421-200010000-00007","article-title":"Cellular immune profile of patients with advanced cancer before and after taxane treatment","volume":"23","author":"Tong","year":"2000","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0370","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bjc.6600347","article-title":"Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes","volume":"87","author":"Tsavaris","year":"2002","journal-title":"Br J Cancer"},{"issue":"18","key":"10.1093\/annonc\/mdy551_bb0375","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1158\/1078-0432.CCR-10-0733","article-title":"A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers","volume":"16","author":"Kodumudi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdy551_bb0380","doi-asserted-by":"crossref","first-page":"286170","DOI":"10.1155\/2014\/286170","article-title":"Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer","volume":"2014","author":"Li","year":"2014","journal-title":"J Immunol Res"},{"issue":"10","key":"10.1093\/annonc\/mdy551_bb0385","doi-asserted-by":"crossref","first-page":"e27025","DOI":"10.4161\/onci.27025","article-title":"Effects of conventional therapeutic interventions on the number and function of regulatory T cells","volume":"2","author":"Roselli","year":"2013","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1093\/annonc\/mdy551_bb0390","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clim.2008.07.013","article-title":"Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy","volume":"129","author":"Zhang","year":"2008","journal-title":"Clin Immunol"},{"issue":"10","key":"10.1093\/annonc\/mdy551_bb0395","first-page":"3025","article-title":"Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy","volume":"7","author":"Demaria","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0400","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/exd.13417","article-title":"Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages","volume":"27","author":"Fujimura","year":"2018","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1093\/annonc\/mdy551_bb0405","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ijc.25813","article-title":"Bystander effect of vinorelbine alters antitumor immune response","volume":"129","author":"Thomas-Schoemann","year":"2011","journal-title":"Int J Cancer"},{"issue":"17","key":"10.1093\/annonc\/mdy551_bb0410","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/0008-5472.CAN-09-1106","article-title":"Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation","volume":"69","author":"Tanaka","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"10.1093\/annonc\/mdy551_bb0415","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdy551_bb0420","series-title":"Cyclophosphamide Prescribing Information","first-page":"118","author":"Food and Drug Administration","year":"2013"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0425","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/s12885-016-2597-2","article-title":"Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators","volume":"16","author":"Wu","year":"2016","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdy551_bb0430","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"10.1093\/annonc\/mdy551_bb0435","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00262-001-0237-3","article-title":"Th2\/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model","volume":"50","author":"Matar","year":"2002","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1093\/annonc\/mdy551_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2017.2579","article-title":"Effect of modified vaccinia Ankara-5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer a randomized clinical trial","volume":"3","author":"Scurr","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0445","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-017-4570-4","article-title":"Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer","volume":"168","author":"Kwa","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1093\/annonc\/mdy551_bb0450","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2249.2007.03521.x","article-title":"Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes","volume":"150","author":"Audia","year":"2007","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1093\/annonc\/mdy551_bb0455","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1093\/annonc\/mdy551_bb0460","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","article-title":"The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy","volume":"78","author":"Ahlmann","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1093\/annonc\/mdy551_bb0465","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1001483","article-title":"Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells","volume":"186","author":"Medina-Echeverz","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"10.1093\/annonc\/mdy551_bb0470","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/jid.2012.341","article-title":"Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent","volume":"133","author":"Ugurel","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"58","key":"10.1093\/annonc\/mdy551_bb0475","doi-asserted-by":"crossref","first-page":"97920","DOI":"10.18632\/oncotarget.18542","article-title":"Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma","volume":"8","author":"Ock","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1093\/annonc\/mdy551_bb0480","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-17-0235","article-title":"Cisplatin alters antitumor immunity and synergizes with PD-1\/PD-L1 inhibition in head and neck squamous cell carcinoma","volume":"5","author":"Tran","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"10.1093\/annonc\/mdy551_bb0485","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2226::AID-CNCR18>3.0.CO;2-X","article-title":"Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation","volume":"85","author":"Garzetti","year":"1999","journal-title":"Cancer"},{"issue":"12","key":"10.1093\/annonc\/mdy551_bb0490","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00262-012-1307-4","article-title":"Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo","volume":"61","author":"Jackaman","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1093\/annonc\/mdy551_bb0495","first-page":"3293","article-title":"Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface","volume":"20","author":"Nio","year":"2000","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1093\/annonc\/mdy551_bb0500","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/cei.12060","article-title":"The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation","volume":"172","author":"Hu","year":"2013","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0505","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12026-015-8734-1","article-title":"Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model","volume":"64","author":"Huang","year":"2016","journal-title":"Immunol Res"},{"issue":"7","key":"10.1093\/annonc\/mdy551_bb0510","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00262-011-1189-x","article-title":"The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues","volume":"61","author":"Tel","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"10.1093\/annonc\/mdy551_bb0515","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03baB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2016.12.180","article-title":"Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model","volume":"487","author":"Wang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdy551_bb0525","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jinorgbio.2016.06.021","article-title":"Anticancer metal drugs and immunogenic cell death","volume":"165","author":"Terenzi","year":"2016","journal-title":"J Inorg Biochem"},{"issue":"4","key":"10.1093\/annonc\/mdy551_bb0530","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0535","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdy551_bb0540","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12094-013-1079-0","article-title":"Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer","volume":"16","author":"Homma","year":"2014","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy551_bb0545","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1093\/annonc\/mdy551_bb0550","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00002281-199106000-00006","article-title":"Methotrexate: mechanism of action, pharmacokinetics, clinical indications, and toxicity","volume":"3","author":"Grosflam","year":"1991","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0555","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1479-5876-7-58","article-title":"Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations","volume":"7","author":"Kaneno","year":"2009","journal-title":"J Transl Med"},{"issue":"10","key":"10.1093\/annonc\/mdy551_bb0560","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/00001813-200311000-00010","article-title":"Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells","volume":"14","author":"Galetto","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdy551_bb0565","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.12659\/MSM.902426","article-title":"Immunogenic chemotherapy sensitizes renal cancer to immune checkpoint blockade therapy in preclinical models","volume":"23","author":"Cui","year":"2017","journal-title":"Med Sci Monit"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0570","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1200\/JCO.2017.35.15_suppl.9094","article-title":"First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: updated results of KEYNOTE-021 cohort G","volume":"35","author":"Papadimitrakopoulou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy551_bb0575","doi-asserted-by":"crossref","first-page":"e61895","DOI":"10.1371\/journal.pone.0061895","article-title":"Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity","volume":"8","author":"Lesterhuis","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1093\/annonc\/mdy551_bb0580","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1111\/cas.13337","article-title":"Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models","volume":"108","author":"Iida","year":"2017","journal-title":"Cancer Sci"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0585","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2016.34.15_suppl.1009","article-title":"Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC)","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy551_bb0590","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2018.06.033","article-title":"Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer","volume":"101","author":"Liu","year":"2018","journal-title":"Eur J Cancer"},{"issue":"23","key":"10.1093\/annonc\/mdy551_bb0595","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0600","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1200\/JCO.2017.35.15_suppl.9082","article-title":"Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade","volume":"35","author":"Grigg","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy551_bb0605","article-title":"Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +\/\u2212 bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)","volume":"28(Suppl 11)","author":"Reck","year":"2017","journal-title":"Ann Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0610","article-title":"Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy","volume":"36","author":"Vida","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy551_bb0615","article-title":"JAVELIN Head and Neck 100: a phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer","author":"Yu","year":"2018","journal-title":"Futur Oncol"},{"key":"10.1093\/annonc\/mdy551_bb0620","series-title":"ASCO","first-page":"145114","article-title":"Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC)","author":"Loibl","year":"2018"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0625","doi-asserted-by":"crossref","first-page":"TPS3116","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3116","article-title":"A phase Ib study evaluating the safety and tolerability of durvalumab in combination with eribulin in patients with HER2-negative metastatic breast cancer and recurrent ovarian cancer","volume":"36","author":"Landry","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0630","doi-asserted-by":"crossref","first-page":"9558","DOI":"10.1200\/JCO.2018.36.15_suppl.9558","article-title":"Chemoimmunotherapy combination after PD-1 inhibitor failure to improve clinical outcomes in metastatic melanoma patients","volume":"36","author":"Vera Aguilera","year":"2018","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdy551_bb0635","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1093\/annonc\/mdy551_bb0640","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy551_bb0645","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na\u00efve patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest New Drugs"},{"issue":"17","key":"10.1093\/annonc\/mdy551_bb0650","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy551_bb0655","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.eururo.2017.12.001","article-title":"Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes","volume":"73","author":"Galsky","year":"2017","journal-title":"Eur Urol"},{"issue":"30","key":"10.1093\/annonc\/mdy551_bb0660","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1200\/JCO.2016.71.7629","article-title":"Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer","volume":"35","author":"Govindan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy551_bb0665","doi-asserted-by":"crossref","first-page":"TPS46","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS46","article-title":"Phase 1\/2 study of safety\/efficacy using trabectedin, ipilimumab, and nivolumab as first-line treatment of advanced soft tissue sarcoma (STS)","volume":"36","author":"Gordon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdy551_bb0670","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1093\/annonc\/mdw416","article-title":"Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study","volume":"27","author":"Kanda","year":"2016","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1093\/annonc\/mdy551_bb0675","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum\u2010based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0680","doi-asserted-by":"crossref","first-page":"TPS1118","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS1118","article-title":"A randomized phase II trial of carboplatin with or without nivolumab in first- or second-line metastatic TNBC","volume":"36","author":"Garrido-Castro","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0685","doi-asserted-by":"crossref","first-page":"TPS4131","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4131","article-title":"An investigator initiated multicenter phase I\/II study of paclitaxel, ramucirumab with nivolumab as the second-line treatment in patients with metastatic gastric cancer","volume":"36","author":"Nishina","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0690","doi-asserted-by":"crossref","first-page":"TPS1110","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS1110","article-title":"Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial)","volume":"36","author":"Ozaki","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0695","doi-asserted-by":"crossref","first-page":"TPS8582","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8582","article-title":"Nivolumab plus cisplatin\/pemetrexed or cisplatin\/gemcitabine as induction in resectable NSCLC","volume":"36","author":"Evans","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0700","doi-asserted-by":"crossref","first-page":"e23568","DOI":"10.1200\/JCO.2018.36.15_suppl.e23568","article-title":"Clinical experience with combination chemo-\/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma","volume":"36","author":"Chawla","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy551_bb0705","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1016\/j.cllc.2018.05.001","article-title":"A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol","volume":"19","author":"Fujimoto","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0710","first-page":"556","article-title":"Safety and efficacy study of pembrolizumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for participants with triple negative breast cancer (TNBC) (MK-3475-173\/KEYNOTE 173)","volume":"35","author":"Bhatti","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy551_bb0715","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/bjc.2017.145","article-title":"A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)","volume":"117","author":"Weiss","year":"2017","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdy551_bb0720","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0725","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1200\/JCO.2017.35.15_suppl.11563","article-title":"Combining chemotherapy and programmed death 1 (PD-1) blockade to induce a T-cell response in patients with metastatic triple negative breast cancer (mTNBC)","volume":"35","author":"Obeid","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdy551_bb0730","first-page":"PD6","article-title":"Abstract PD6-13: phase 1b\/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer","volume":"78","author":"Tolaney","year":"2018","journal-title":"Cancer Res"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0735","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1200\/JCO.2018.36.15_suppl.1033","article-title":"Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC)","volume":"36","author":"Page","year":"2018","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1093\/annonc\/mdy551_bb0740","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1093\/annonc\/mdy551_bb0745","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0750","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2018.36.15_suppl.105","article-title":"Phase 3 study of carboplatin-paclitaxel\/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC)","volume":"36","author":"Paz-Ares","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy551_bb0755","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.clgc.2018.07.004","article-title":"Pembrolizumab combined with either docetaxel or gemcitabine in patients with advanced or metastatic platinum-refractory urothelial cancer: results from a phase I study","volume":"16","author":"Parikh","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdy551_bb0760","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/annonc\/mdu205","article-title":"A phase I dose escalation trial of tremelimumab (CP-675, 206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer","volume":"25","author":"Aglietta","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy551_bb0765","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"10.1093\/annonc\/mdy551_bb0770","doi-asserted-by":"crossref","unstructured":"Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial. Ann Oncol2017; 28(Suppl 5): v605\u2013v649. doi: 10.1093\/annonc\/mdx440.","DOI":"10.1093\/annonc\/mdx440"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy551_bb0775","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.2018.36.15_suppl.1012","article-title":"Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): final response data stage I and first translational data","volume":"36","author":"Kok","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy551_bb0780","doi-asserted-by":"crossref","first-page":"G52","DOI":"10.1016\/j.vaccine.2009.09.106","article-title":"Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages","volume":"27","author":"Gray","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1093\/annonc\/mdy551_bb0785","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S1567-5769(03)00021-3","article-title":"Immunomodulation in cancer therapeutics","volume":"3","author":"Ehrke","year":"2003","journal-title":"Int Immunopharmacol"},{"issue":"13","key":"10.1093\/annonc\/mdy551_bb0790","first-page":"3572","article-title":"Adriamycin-induced modulation of host defenses in tumor-bearing mice","volume":"52","author":"Maccubbin","year":"1992","journal-title":"Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419310440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419310440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/2\/219\/27970070\/mdy551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:56:26Z","timestamp":1624683386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419310440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":157,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0923753419310440"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy551","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}